Immunotherapy techniques, including single-agent and combination medicines, are the recommended therapeutic options for endometrial cancer patients. Recent clinical trials have shown the efficacy of immunotherapy in the first and second lines of treatment. In certain patient subgroups, single-agent immunotherapy has shown promise in lowering the requirement for chemotherapy. Improved molecular characterization has transformed the treatment of endometrial cancer patients. The identification of various subgroups of endometrial cancer based on mutation status, which correlates strongly with overall survival, has been made possible by molecular profiling. In studies such as PORTEC-2, these subgroups have been verified. Patients with POLE mutations, who have a high level of mutation and fare exceedingly well, are one of the subgroups; patients with mismatch repair deficits, who also have a large number of mutations, are another.

To know more: About the original article click here.